The tumor-infiltrating lymphocyte ultrasonography score can provide a diagnostic prediction of lymphocyte-predominant breast cancer preoperatively.
Breast cancer
Lymphocyte-predominant breast cancer
Tumor-infiltrating lymphocytes
Ultrasonography
Journal
Journal of medical ultrasonics (2001)
ISSN: 1613-2254
Titre abrégé: J Med Ultrason (2001)
Pays: Japan
ID NLM: 101128385
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
02
05
2022
accepted:
08
06
2022
pubmed:
25
8
2022
medline:
10
11
2022
entrez:
24
8
2022
Statut:
ppublish
Résumé
Tumor-infiltrating lymphocytes (TILs) are known to predict the therapeutic effect in breast cancer. Although a preoperative tissue biopsy can be used to evaluate TILs, TILs that are heterogeneously distributed might require examination of all preoperative tissue biopsy samples. We have recently reported that the TIL ultrasonography (US) score, as determined by characteristic US findings, provides excellent predictive performance for lymphocyte predominant breast cancer (LPBC). We herein aimed to determine whether the preoperative TIL-US score can more accurately predict LPBC than preoperative tissue biopsy. We assessed 161 patients with invasive breast cancer that were treated with curative surgery between January 2014 and December 2017. Stromal lymphocytes were examined on preoperative tissue biopsy tissues and surgical pathological specimens. Breast cancer samples with ≥ 50% stromal TILs were defined as pre-LPBC (preoperative tissue biopsy) and LPBC (surgical pathological specimens). Useful factors for predicting LPBC were searched among clinicopathological factors. The TIL-US score cutoff value for predicting LPBC was 4 points based on the receiver operating characteristic curves (area under the curve: 0.88). Several significant predictors for LPBC were revealed by the undertaken multivariate logistic regression analysis (odds ratios: TIL-US score, 26.8; pre-LPBC, 18.6; HER2, 9.2; all, p < 0.05). The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 0.74, 0.89, 0.85, 0.67, and 0.92 for the TIL-US score, respectively, and 0.51, 0.98, 0.87, 0.91, and 0.86 for the pre-LPBC, respectively. TIL-US scores can predict LPBC preoperatively and are characterized by a significantly high sensitivity and negative predictive value.
Identifiants
pubmed: 36002708
doi: 10.1007/s10396-022-01240-4
pii: 10.1007/s10396-022-01240-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
709-717Informations de copyright
© 2022. The Author(s), under exclusive licence to The Japan Society of Ultrasonics in Medicine.
Références
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70.
doi: 10.1126/science.1203486
pubmed: 21436444
Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959–66.
doi: 10.1200/JCO.2013.55.0491
pubmed: 25071121
pmcid: 4162494
Ali HR, Provenzano E, Dawson SJ, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014;25:1536–43.
doi: 10.1093/annonc/mdu191
pubmed: 24915873
Dieci MV, Criscitiello C, Goubar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25:611–8.
doi: 10.1093/annonc/mdt556
pubmed: 24401929
pmcid: 3933248
Perez EA, Ballman KV, Tenner KS, et al. Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer. JAMA Oncol. 2016;2:56–64.
doi: 10.1001/jamaoncol.2015.3239
pubmed: 26469139
pmcid: 4713247
Salgado R, Denkert C, Campbell C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO Trial. JAMA Oncol. 2015;1:448–54.
doi: 10.1001/jamaoncol.2015.0830
pubmed: 26181252
pmcid: 5551492
Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25:1544–50.
doi: 10.1093/annonc/mdu112
pubmed: 24608200
Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol. 2013;31:860–7.
doi: 10.1200/JCO.2011.41.0902
pubmed: 23341518
Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:105–13.
doi: 10.1200/JCO.2009.23.7370
pubmed: 19917869
Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33:983–91.
doi: 10.1200/JCO.2014.58.1967
pubmed: 25534375
Issa-Nummer Y, Darb-Esfahani S, Loibl S, et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer–A substudy of the neoadjuvant GeparQuinto trial. PLoS ONE. 2013;8: e79775.
doi: 10.1371/journal.pone.0079775
pubmed: 24312450
pmcid: 3846472
West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13:R126.
doi: 10.1186/bcr3072
pubmed: 22151962
pmcid: 3326568
Ingold Heppner B, Untch M, Denkert C, et al. Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer. Clin Cancer Res. 2016;22:5747–54.
doi: 10.1158/1078-0432.CCR-15-2338
pubmed: 27189162
Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40–50.
doi: 10.1016/S1470-2045(17)30904-X
pubmed: 29233559
Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International Tils Working Group 2014. Ann Oncol. 2015;26:259–71.
doi: 10.1093/annonc/mdu450
pubmed: 25214542
Denkert C, Wienert S, Poterie A, et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol. 2016;29:1155–64.
doi: 10.1038/modpathol.2016.109
pubmed: 27363491
Swisher SK, Wu Y, Castaneda CA, et al. Interobserver agreement between pathologists assessing tumor-infiltrating lymphocytes (TILs) in breast cancer using methodology proposed by the International Tils Working Group. Ann Surg Oncol. 2016;23:2242–8.
doi: 10.1245/s10434-016-5173-8
pubmed: 26965699
Khoury T, Peng X, Yan L, Wang D, Nagrale V. Tumor-infiltrating lymphocytes in breast cancer: evaluating interobserver variability, heterogeneity, and fidelity of scoring core biopsies. Am J Clin Pathol. 2018;150:441–50.
doi: 10.1093/ajcp/aqy069
pubmed: 30052720
Crystal P, Strano SD, Shcharynski S, Koretz MJ. Using sonography to screen women with mammographically dense breasts. AJR. 2003;181:177–82.
doi: 10.2214/ajr.181.1.1810177
pubmed: 12818853
Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology. 2002;225:165–75.
doi: 10.1148/radiol.2251011667
pubmed: 12355001
Weinstein SP, Localio AR, Conant EF, Rosen M, Thomas KM, Schnall MD. Multimodality screening of high-risk women: a prospective cohort study. J Clin Oncol. 2009;27:6124–8.
doi: 10.1200/JCO.2009.24.4277
pubmed: 19884532
pmcid: 2793033
Berg WA, Blume JD, Cormack JB, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008;299:2151–63.
doi: 10.1001/jama.299.18.2151
pubmed: 18477782
pmcid: 2718688
Tohno E, Umemoto T, Sasaki K, Morishima I, Ueno E. Effect of adding screening ultrasonography to screening mammography on patient recall and cancer detection rates: a retrospective study in Japan. Eur J Radiol. 2013;82:1227–30.
doi: 10.1016/j.ejrad.2013.02.007
pubmed: 23465737
Tohno E, Takahashi H, Tamada T, Fujimoto Y, Yasuda H, Ohuchi N. Educational program and testing using images for the standardization of breast cancer screening by ultrasonography. Breast Cancer. 2012;19:138–46.
doi: 10.1007/s12282-010-0221-x
pubmed: 20924733
Ohuchi N, Suzuki A, Sobue T, et al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial. Lancet. 2016;387:341–8.
doi: 10.1016/S0140-6736(15)00774-6
pubmed: 26547101
Chen SC, Cheung YC, Su CH, Chen MF, Hwang TL, Hsueh S. Analysis of sonographic features for the differentiation of benign and malignant breast tumors of different sizes. Ultrasound Obstet Gynecol. 2004;23:188–93.
doi: 10.1002/uog.930
pubmed: 14770402
Costantini M, Belli P, Lombardi R, Franceschini G, Mulè A, Bonomo L. Characterization of solid breast masses: use of the sonographic breast imaging reporting and data system lexicon. J Ultrasound Med. 2006;25:649–59.
doi: 10.7863/jum.2006.25.5.649
pubmed: 16632790
Rahbar G, Sie AC, Hansen GC, et al. Benign versus malignant solid breast masses: US differentiation. Radiology. 1999;213:889–94.
doi: 10.1148/radiology.213.3.r99dc20889
pubmed: 10580971
Fukui K, Masumoto N, Shiroma N, et al. Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer. Breast Cancer. 2019;26:573–80.
doi: 10.1007/s12282-019-00958-3
pubmed: 30868399
Dieci MV, Mathieu MC, Guarneri V, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol. 2015;26:1698–704.
doi: 10.1093/annonc/mdv239
pubmed: 25995301
pmcid: 4511223
Çelebi F, Agacayak F, Ozturk A, et al. Usefulness of imaging findings in predicting tumor-infiltrating lymphocytes in patients with breast cancer. Eur Radiol. 2020;30:2049–57.
doi: 10.1007/s00330-019-06516-x
pubmed: 31822972
Jang N, Kwon HJ, Park MH, Kang SH, Bae YK. Prognostic value of tumor-infiltrating lymphocyte density assessed using a standardized method based on molecular subtypes and adjuvant chemotherapy in invasive breast cancer. Ann Surg Oncol. 2018;25:937–46.
doi: 10.1245/s10434-017-6332-2
pubmed: 29330719
Dieci MV, Radosevic-Robin N, Fineberg S, et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International immuno-oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol. 2018;52:16–25.
doi: 10.1016/j.semcancer.2017.10.003
pubmed: 29024776
Hamy AS, Pierga JY, Sabaila A, et al. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. Ann Oncol. 2017;28:2233–40.
doi: 10.1093/annonc/mdx309
pubmed: 28911063